HKEX: 2696
(1) Changes in non-executive director and independent non-executive director (2) appointment of chairman of the board and changes in composition of the board committees
View original source (HKEXnews)Company analysis
Earlier from Shanghai Henlius Biotech, Inc. Class H
- Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation
- Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation, and Accelerating Progress Towards C-MNC
- Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform
- FDA Approves Shanghai Henlius Biotech IND For Cetuximab Biosimilar